Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma.

Adilijiang A, Hirano M, Okuno Y, Aoki K, Ohka F, Maeda S, Tanahashi K, Motomura K, Shimizu H, Yamaguchi J, Wakabayashi T, Natsume A.

Molecules. 2019 Aug 22;24(17). pii: E3046. doi: 10.3390/molecules24173046.

2.

Pathogenic Epigenetic Consequences of Genetic Alterations in IDH-Wild-Type Diffuse Astrocytic Gliomas.

Ohka F, Shinjo K, Deguchi S, Matsui Y, Okuno Y, Katsushima K, Suzuki M, Kato A, Ogiso N, Yamamichi A, Aoki K, Suzuki H, Sato S, Arul Rayan N, Prabhakar S, Göke J, Shimamura T, Maruyama R, Takahashi S, Suzumura A, Kimura H, Wakabayashi T, Zong H, Natsume A, Kondo Y.

Cancer Res. 2019 Oct 1;79(19):4814-4827. doi: 10.1158/0008-5472.CAN-19-1272. Epub 2019 Aug 20.

PMID:
31431463
3.

Spontaneous Tumor Regression of Intracranial Solitary Fibrous Tumor Originating From the Medulla Oblongata: A Case Report and Literature Review.

Yamaguchi J, Motomura K, Ohka F, Aoki K, Tanahashi K, Hirano M, Nishikawa T, Shimizu H, Wakabayashi T, Natsume A.

World Neurosurg. 2019 Oct;130:400-404. doi: 10.1016/j.wneu.2019.07.052. Epub 2019 Jul 18.

PMID:
31326640
4.

Neurocognitive and functional outcomes in patients with diffuse frontal lower-grade gliomas undergoing intraoperative awake brain mapping.

Motomura K, Chalise L, Ohka F, Aoki K, Tanahashi K, Hirano M, Nishikawa T, Yamaguchi J, Shimizu H, Wakabayashi T, Natsume A.

J Neurosurg. 2019 May 17:1-9. doi: 10.3171/2019.3.JNS19211. [Epub ahead of print]

PMID:
31100731
5.

Aberrant Active cis-Regulatory Elements Associated with Downregulation of RET Finger Protein Overcome Chemoresistance in Glioblastoma.

Ranjit M, Hirano M, Aoki K, Okuno Y, Ohka F, Yamamichi A, Kato A, Maeda S, Motomura K, Matsuo K, Enomoto A, Ino Y, Todo T, Takahashi M, Wakabayashi T, Kato T, Natsume A.

Cell Rep. 2019 Feb 26;26(9):2274-2281.e5. doi: 10.1016/j.celrep.2019.01.109.

6.

Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study.

Wee CW, Kim IH, Park CK, Kim JW, Dho YS, Ohka F, Aoki K, Motomura K, Natsume A, Kim N, Suh CO, Chang JH, Kim SH, Cho WK, Lim DH, Nam DH, Choi JW, Kim IA, Kim CY, Oh YT, Cho O, Chung WK, Kim SH, Kim E.

Radiother Oncol. 2018 Nov;129(2):347-351. doi: 10.1016/j.radonc.2018.09.001. Epub 2018 Sep 17.

PMID:
30236994
7.

Characterization of Intraoperative Motor Evoked Potential Monitoring for Surgery of the Pediatric Population with Brain Tumors.

Motomura K, Sumita K, Chalise L, Nishikawa T, Tanahashi K, Ohka F, Aoki K, Hirano M, Nakamura T, Matsushita T, Wakabayashi T, Natsume A.

World Neurosurg. 2018 Nov;119:e1052-e1059. doi: 10.1016/j.wneu.2018.08.039. Epub 2018 Aug 16.

PMID:
30121408
8.

Supratotal Resection of Diffuse Frontal Lower Grade Gliomas with Awake Brain Mapping, Preserving Motor, Language, and Neurocognitive Functions.

Motomura K, Chalise L, Ohka F, Aoki K, Tanahashi K, Hirano M, Nishikawa T, Wakabayashi T, Natsume A.

World Neurosurg. 2018 Nov;119:30-39. doi: 10.1016/j.wneu.2018.07.193. Epub 2018 Aug 1.

PMID:
30075269
9.

Neuroendoscopic Cylinder Surgery and 5-Aminolevulinic Acid Photodynamic Diagnosis of Deep-Seated Intracranial Lesions.

Choo J, Takeuchi K, Nagata Y, Ohka F, Kishida Y, Watanabe T, Satoh Y, Nagatani T, Kato K, Wakabayashi T, Natsume A.

World Neurosurg. 2018 Aug;116:e35-e41. doi: 10.1016/j.wneu.2018.03.112. Epub 2018 Mar 23.

PMID:
29581022
10.

Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion.

Yamamichi A, Ohka F, Aoki K, Suzuki H, Kato A, Hirano M, Motomura K, Tanahashi K, Chalise L, Maeda S, Wakabayashi T, Kato Y, Natsume A.

Brain Tumor Pathol. 2018 Apr;35(2):106-113. doi: 10.1007/s10014-018-0312-5. Epub 2018 Mar 17.

PMID:
29550880
11.

A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR.

Hirano M, Ohka F, Maeda S, Chalise L, Yamamichi A, Aoki K, Kato A, Tanahashi K, Motomura K, Nishimura Y, Hara M, Shinjo K, Kondo Y, Wakabayashi T, Natsume A.

Brain Tumor Pathol. 2018 Apr;35(2):97-105. doi: 10.1007/s10014-018-0310-7. Epub 2018 Feb 19.

PMID:
29460200
12.

Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.

Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T, Motomura K, Ohka F, Shiina S, Yamamoto T, Nagata Y, Yoshizato T, Mizoguchi M, Abe T, Momii Y, Muragaki Y, Watanabe R, Ito I, Sanada M, Yajima H, Morita N, Takeuchi I, Miyano S, Wakabayashi T, Ogawa S, Natsume A.

Neuro Oncol. 2018 Jan 10;20(1):66-77. doi: 10.1093/neuonc/nox132.

13.

Organotypic brain explant culture as a drug evaluation system for malignant brain tumors.

Minami N, Maeda Y, Shibao S, Arima Y, Ohka F, Kondo Y, Maruyama K, Kusuhara M, Sasayama T, Kohmura E, Saya H, Sampetrean O.

Cancer Med. 2017 Nov;6(11):2635-2645. doi: 10.1002/cam4.1174. Epub 2017 Oct 4.

14.

Remote ischemic preconditioning protects human neural stem cells from oxidative stress.

Motomura A, Shimizu M, Kato A, Motomura K, Yamamichi A, Koyama H, Ohka F, Nishikawa T, Nishimura Y, Hara M, Fukuda T, Bando Y, Nishimura T, Wakabayashi T, Natsume A.

Apoptosis. 2017 Nov;22(11):1353-1361. doi: 10.1007/s10495-017-1425-8.

PMID:
28951984
15.

Significance of perivascular tumour cells defined by CD109 expression in progression of glioma.

Shiraki Y, Mii S, Enomoto A, Momota H, Han YP, Kato T, Ushida K, Kato A, Asai N, Murakumo Y, Aoki K, Suzuki H, Ohka F, Wakabayashi T, Todo T, Ogawa S, Natsume A, Takahashi M.

J Pathol. 2017 Dec;243(4):468-480. doi: 10.1002/path.4981. Epub 2017 Nov 1.

PMID:
28888050
16.
17.

Negative impact of leukoaraiosis on the incidence of brain metastases in patients with lung cancer.

Hayashi N, Mitsuya K, Nakasu Y, Naito T, Ohka F, Takahashi T.

J Neurooncol. 2017 Nov;135(2):299-306. doi: 10.1007/s11060-017-2574-x. Epub 2017 Jul 27.

18.

Significance of low mTORC1 activity in defining the characteristics of brain tumor stem cells.

Han YP, Enomoto A, Shiraki Y, Wang SQ, Wang X, Toyokuni S, Asai N, Ushida K, Ara H, Ohka F, Wakabayashi T, Ma J, Natsume A, Takahashi M.

Neuro Oncol. 2017 May 1;19(5):636-647. doi: 10.1093/neuonc/now237.

19.

Oncogenic effects of evolutionarily conserved noncoding RNA ECONEXIN on gliomagenesis.

Deguchi S, Katsushima K, Hatanaka A, Shinjo K, Ohka F, Wakabayashi T, Zong H, Natsume A, Kondo Y.

Oncogene. 2017 Aug 10;36(32):4629-4640. doi: 10.1038/onc.2017.88. Epub 2017 Apr 3.

PMID:
28368417
20.

A novel all-in-one intraoperative genotyping system for IDH1-mutant glioma.

Ohka F, Yamamichi A, Kurimoto M, Motomura K, Tanahashi K, Suzuki H, Aoki K, Deguchi S, Chalise L, Hirano M, Kato A, Nishimura Y, Hara M, Kato Y, Wakabayashi T, Natsume A.

Brain Tumor Pathol. 2017 Apr;34(2):91-97. doi: 10.1007/s10014-017-0281-0. Epub 2017 Mar 28.

PMID:
28353033
21.

Girdin maintains the stemness of glioblastoma stem cells.

Natsume A, Kato T, Kinjo S, Enomoto A, Toda H, Shimato S, Ohka F, Motomura K, Kondo Y, Miyata T, Takahashi M, Wakabayashi T.

Oncogene. 2017 Jun 29;36(26):3796. doi: 10.1038/onc.2017.17. Epub 2017 Feb 20.

PMID:
28218901
22.

Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities.

Kuramitsu S, Yamamichi A, Ohka F, Motomura K, Hara M, Natsume A.

Immunotherapy. 2016 Dec;8(12):1393-1404. doi: 10.2217/imt-2016-0076. Review.

PMID:
28000534
23.

Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment.

Katsushima K, Natsume A, Ohka F, Shinjo K, Hatanaka A, Ichimura N, Sato S, Takahashi S, Kimura H, Totoki Y, Shibata T, Naito M, Kim HJ, Miyata K, Kataoka K, Kondo Y.

Nat Commun. 2016 Dec 6;7:13616. doi: 10.1038/ncomms13616.

24.

An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas.

Yamamichi A, Kasama T, Ohka F, Suzuki H, Kato A, Motomura K, Hirano M, Ranjit M, Chalise L, Kurimoto M, Kondo G, Aoki K, Kaji N, Tokeshi M, Matsubara T, Senga T, Kaneko MK, Suzuki H, Hara M, Wakabayashi T, Baba Y, Kato Y, Natsume A.

Sci Technol Adv Mater. 2016 Oct 4;17(1):618-625. eCollection 2016.

25.

[The mechanisms'of glioma formation: Insights into molecular mechanism and cell of origin].

Ohka F, Suzuki H, Aoki K, Natsume A.

Nihon Rinsho. 2016 Sep;74 Suppl 7:167-171. Japanese. No abstract available.

PMID:
30634749
26.

[CIC].

Suzuki H, Aoki K, Ohka F, Natsume A.

Nihon Rinsho. 2016 Sep;74 Suppl 7:143-147. Japanese. No abstract available.

PMID:
30634745
27.

[IDH1, IDH2].

Suzuki H, Aoki K, Ohka F, Natsume A.

Nihon Rinsho. 2016 Sep;74 Suppl 7:117-121. Japanese. No abstract available.

PMID:
30634740
28.

LATS2 Positively Regulates Polycomb Repressive Complex 2.

Torigata K, Daisuke O, Mukai S, Hatanaka A, Ohka F, Motooka D, Nakamura S, Ohkawa Y, Yabuta N, Kondo Y, Nojima H.

PLoS One. 2016 Jul 19;11(7):e0158562. doi: 10.1371/journal.pone.0158562. eCollection 2016.

29.

Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320-Mediated Suppression of the Androgen Receptor.

Sato S, Katsushima K, Shinjo K, Hatanaka A, Ohka F, Suzuki S, Naiki-Ito A, Soga N, Takahashi S, Kondo Y.

Cancer Res. 2016 Jul 15;76(14):4192-204. doi: 10.1158/0008-5472.CAN-15-3339. Epub 2016 May 23.

30.

CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains.

Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A, Motomura K, Tanahashi K, Yamamoto T, Watanabe R, Ito I, Senga T, Hamaguchi M, Wakabayashi T, Kaneko MK, Kato Y, Chandramohan V, Bigner DD, Natsume A.

Cancer Immunol Res. 2016 Mar;4(3):259-68. doi: 10.1158/2326-6066.CIR-15-0060. Epub 2016 Jan 28.

31.

Rapid sensitive analysis of IDH1 mutation in lower-grade gliomas by automated genetic typing involving a quenching probe.

Kurimoto M, Suzuki H, Aoki K, Ohka F, Kondo G, Motomura K, Iijima K, Yamamichi A, Ranjit M, Wakabayashi T, Kimura S, Natsume A.

Cancer Invest. 2016;34(1):12-5. doi: 10.3109/07357907.2015.1084001. Epub 2015 Dec 22.

PMID:
26695622
32.

Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.

Kuramitsu S, Ohno M, Ohka F, Shiina S, Yamamichi A, Kato A, Tanahashi K, Motomura K, Kondo G, Kurimoto M, Senga T, Wakabayashi T, Natsume A.

Cancer Gene Ther. 2015 Oct;22(10):487-95. doi: 10.1038/cgt.2015.47. Epub 2015 Oct 9.

PMID:
26450624
33.

Applicable advances in the molecular pathology of glioblastoma.

Ranjit M, Motomura K, Ohka F, Wakabayashi T, Natsume A.

Brain Tumor Pathol. 2015 Jul;32(3):153-62. doi: 10.1007/s10014-015-0224-6. Epub 2015 Jun 16. Review.

PMID:
26078107
34.

Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer.

Ichimura N, Shinjo K, An B, Shimizu Y, Yamao K, Ohka F, Katsushima K, Hatanaka A, Tojo M, Yamamoto E, Suzuki H, Ueda M, Kondo Y.

Cancer Prev Res (Phila). 2015 Aug;8(8):702-11. doi: 10.1158/1940-6207.CAPR-14-0306. Epub 2015 Jun 10.

35.

Activation of Yes-Associated Protein in Low-Grade Meningiomas Is Regulated by Merlin, Cell Density, and Extracellular Matrix Stiffness.

Tanahashi K, Natsume A, Ohka F, Motomura K, Alim A, Tanaka I, Senga T, Harada I, Fukuyama R, Sumiyoshi N, Sekido Y, Wakabayashi T.

J Neuropathol Exp Neurol. 2015 Jul;74(7):704-9. doi: 10.1097/NEN.0000000000000211.

PMID:
26049897
36.

Mutational landscape and clonal architecture in grade II and III gliomas.

Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, Shimamura T, Niida A, Motomura K, Ohka F, Yamamoto T, Tanahashi K, Ranjit M, Wakabayashi T, Yoshizato T, Kataoka K, Yoshida K, Nagata Y, Sato-Otsubo A, Tanaka H, Sanada M, Kondo Y, Nakamura H, Mizoguchi M, Abe T, Muragaki Y, Watanabe R, Ito I, Miyano S, Natsume A, Ogawa S.

Nat Genet. 2015 May;47(5):458-68. doi: 10.1038/ng.3273. Epub 2015 Apr 13.

PMID:
25848751
37.

Assessment of tumor cells in a mouse model of diffuse infiltrative glioma by Raman spectroscopy.

Tanahashi K, Natsume A, Ohka F, Momota H, Kato A, Motomura K, Watabe N, Muraishi S, Nakahara H, Saito Y, Takeuchi I, Wakabayashi T.

Biomed Res Int. 2014;2014:860241. doi: 10.1155/2014/860241. Epub 2014 Aug 27.

38.

Epigenetic dysregulation in glioma.

Kondo Y, Katsushima K, Ohka F, Natsume A, Shinjo K.

Cancer Sci. 2014 Apr;105(4):363-9. Review.

39.

Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.

Ohka F, Ito M, Ranjit M, Senga T, Motomura A, Motomura K, Saito K, Kato K, Kato Y, Wakabayashi T, Soga T, Natsume A.

Tumour Biol. 2014 Jun;35(6):5911-20. doi: 10.1007/s13277-014-1784-5. Epub 2014 Mar 5.

PMID:
24590270
40.

Peptide-based inhibition of the HOXA9/PBX interaction retards the growth of human meningioma.

Ando H, Natsume A, Senga T, Watanabe R, Ito I, Ohno M, Iwami K, Ohka F, Motomura K, Kinjo S, Ito M, Saito K, Morgan R, Wakabayashi T.

Cancer Chemother Pharmacol. 2014 Jan;73(1):53-60. doi: 10.1007/s00280-013-2316-5. Epub 2013 Oct 20.

PMID:
24141373
41.

Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma.

Natsume A, Ito M, Katsushima K, Ohka F, Hatanaka A, Shinjo K, Sato S, Takahashi S, Ishikawa Y, Takeuchi I, Shimogawa H, Uesugi M, Okano H, Kim SU, Wakabayashi T, Issa JP, Sekido Y, Kondo Y.

Cancer Res. 2013 Jul 15;73(14):4559-70. doi: 10.1158/0008-5472.CAN-13-0109. Epub 2013 May 29.

42.

A hypoxia-inducible factor (HIF)-3α splicing variant, HIF-3α4 impairs angiogenesis in hypervascular malignant meningiomas with epigenetically silenced HIF-3α4.

Ando H, Natsume A, Iwami K, Ohka F, Kuchimaru T, Kizaka-Kondoh S, Ito K, Saito K, Sugita S, Hoshino T, Wakabayashi T.

Biochem Biophys Res Commun. 2013 Mar 29;433(1):139-44. doi: 10.1016/j.bbrc.2013.02.044. Epub 2013 Feb 26.

PMID:
23485455
43.

Neural stem cell-based dual suicide gene delivery for metastatic brain tumors.

Wang C, Natsume A, Lee HJ, Motomura K, Nishimira Y, Ohno M, Ito M, Kinjo S, Momota H, Iwami K, Ohka F, Wakabayashi T, Kim SU.

Cancer Gene Ther. 2012 Nov;19(11):796-801. doi: 10.1038/cgt.2012.63. Epub 2012 Sep 28.

PMID:
23018623
44.

Contribution of microRNA-1275 to Claudin11 protein suppression via a polycomb-mediated silencing mechanism in human glioma stem-like cells.

Katsushima K, Shinjo K, Natsume A, Ohka F, Fujii M, Osada H, Sekido Y, Kondo Y.

J Biol Chem. 2012 Aug 10;287(33):27396-406. doi: 10.1074/jbc.M112.359109. Epub 2012 Jun 26.

45.

Current trends in targeted therapies for glioblastoma multiforme.

Ohka F, Natsume A, Wakabayashi T.

Neurol Res Int. 2012;2012:878425. doi: 10.1155/2012/878425. Epub 2012 Mar 5.

46.

Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses.

Kishida Y, Natsume A, Kondo Y, Takeuchi I, An B, Okamoto Y, Shinjo K, Saito K, Ando H, Ohka F, Sekido Y, Wakabayashi T.

Carcinogenesis. 2012 Feb;33(2):436-41. doi: 10.1093/carcin/bgr260. Epub 2011 Nov 18.

PMID:
22102699
47.

Girdin maintains the stemness of glioblastoma stem cells.

Natsume A, Kato T, Kinjo S, Enomoto A, Toda H, Shimato S, Ohka F, Motomura K, Kondo Y, Miyata T, Takahashi M, Wakabayashi T.

Oncogene. 2012 May 31;31(22):2715-24. doi: 10.1038/onc.2011.466. Epub 2011 Oct 24. Erratum in: Oncogene. 2017 Jun 29;36(26):3796.

PMID:
22020337
48.

The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma.

Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, Nakasu Y, Namba H, Wakai K, Fukui T, Momota H, Iwami K, Kinjo S, Ito M, Fujii M, Wakabayashi T.

PLoS One. 2011;6(8):e23332. doi: 10.1371/journal.pone.0023332. Epub 2011 Aug 4.

Supplemental Content

Support Center